Cargando…

Lung function in adult patients with cystic fibrosis after using the eFlow(® )rapid for one year

BACKGROUND: The new generation nebuliser PARI eFlow(® )rapid allows a highly efficient aerosol delivery at reduced inhalation time. However, lung function data during long-term use of this device are not available until now. METHODS: 70 clinically stable adult cystic fibrosis patients participated i...

Descripción completa

Detalles Bibliográficos
Autores principales: Naehrig, S, Lang, S, Schiffl, H, Huber, RM, Fischer, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353423/
https://www.ncbi.nlm.nih.gov/pubmed/21463983
http://dx.doi.org/10.1186/2047-783X-16-2-63
_version_ 1782233044918206464
author Naehrig, S
Lang, S
Schiffl, H
Huber, RM
Fischer, R
author_facet Naehrig, S
Lang, S
Schiffl, H
Huber, RM
Fischer, R
author_sort Naehrig, S
collection PubMed
description BACKGROUND: The new generation nebuliser PARI eFlow(® )rapid allows a highly efficient aerosol delivery at reduced inhalation time. However, lung function data during long-term use of this device are not available until now. METHODS: 70 clinically stable adult cystic fibrosis patients participated in this observation study. Lung function tests were performed prospectively 12 weeks after and again 9 to 12 months after switching the inhalation device from a conventional jet nebulizer to the PARI eFlow(® )rapid. Lung function data were collected retrospectively from the visits 1 year as well as 12 weeks prior to the switch-over. Lung function data for all time points were only available for 59 patients. Treatment time and patient's satification were recorded for both conventional and new nebuliser in all 70 patients. RESULTS: After 1 year of inhalation with eFlow(® )rapid, the mean change in FEV1% was -- 1.4% (n = 59 patients). The decrease in FEV1 was smaller than the change in FEV1 after 1 year of inhalation with the conventional jet nebuliser (control period, -3.1%), although this difference was not statistically significant. The same effect was seen in MEF25[%] '(-2.6% with conventional nebuliser compared to --1.6% after eFlow(® )rapid). Concerning the FVC, there was a greater improvement after 1 year of inhalation with the eFlow(® )rapid than with the jet nebuliser (+ 2.9% vs. +1.1%). For PEF%, there was an increase during the control period, whereas after inhalation with eFlow(® )rapid there was a decrease (+1.1% vs. --2.9%). All changes were not significantly different. The eFlow(® )rapid reduced total daily inhalation time by two-thirds (conventional nebuliser: 31.1 min/day; eFlow(® )rapid: 10.2 min/day, n = 70 patients) CONCLUSION: Inhalation with the new nebuliser eFlow rapid does not alter FEV1, FVC or PEF significantly after 1 year of inhalation. The treatment time could be reduced significantly by the eFlow(® )rapid.
format Online
Article
Text
id pubmed-3353423
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-33534232012-05-16 Lung function in adult patients with cystic fibrosis after using the eFlow(® )rapid for one year Naehrig, S Lang, S Schiffl, H Huber, RM Fischer, R Eur J Med Res Research BACKGROUND: The new generation nebuliser PARI eFlow(® )rapid allows a highly efficient aerosol delivery at reduced inhalation time. However, lung function data during long-term use of this device are not available until now. METHODS: 70 clinically stable adult cystic fibrosis patients participated in this observation study. Lung function tests were performed prospectively 12 weeks after and again 9 to 12 months after switching the inhalation device from a conventional jet nebulizer to the PARI eFlow(® )rapid. Lung function data were collected retrospectively from the visits 1 year as well as 12 weeks prior to the switch-over. Lung function data for all time points were only available for 59 patients. Treatment time and patient's satification were recorded for both conventional and new nebuliser in all 70 patients. RESULTS: After 1 year of inhalation with eFlow(® )rapid, the mean change in FEV1% was -- 1.4% (n = 59 patients). The decrease in FEV1 was smaller than the change in FEV1 after 1 year of inhalation with the conventional jet nebuliser (control period, -3.1%), although this difference was not statistically significant. The same effect was seen in MEF25[%] '(-2.6% with conventional nebuliser compared to --1.6% after eFlow(® )rapid). Concerning the FVC, there was a greater improvement after 1 year of inhalation with the eFlow(® )rapid than with the jet nebuliser (+ 2.9% vs. +1.1%). For PEF%, there was an increase during the control period, whereas after inhalation with eFlow(® )rapid there was a decrease (+1.1% vs. --2.9%). All changes were not significantly different. The eFlow(® )rapid reduced total daily inhalation time by two-thirds (conventional nebuliser: 31.1 min/day; eFlow(® )rapid: 10.2 min/day, n = 70 patients) CONCLUSION: Inhalation with the new nebuliser eFlow rapid does not alter FEV1, FVC or PEF significantly after 1 year of inhalation. The treatment time could be reduced significantly by the eFlow(® )rapid. BioMed Central 2011-02-24 /pmc/articles/PMC3353423/ /pubmed/21463983 http://dx.doi.org/10.1186/2047-783X-16-2-63 Text en Copyright ©2011 I. Holzapfel Publishers
spellingShingle Research
Naehrig, S
Lang, S
Schiffl, H
Huber, RM
Fischer, R
Lung function in adult patients with cystic fibrosis after using the eFlow(® )rapid for one year
title Lung function in adult patients with cystic fibrosis after using the eFlow(® )rapid for one year
title_full Lung function in adult patients with cystic fibrosis after using the eFlow(® )rapid for one year
title_fullStr Lung function in adult patients with cystic fibrosis after using the eFlow(® )rapid for one year
title_full_unstemmed Lung function in adult patients with cystic fibrosis after using the eFlow(® )rapid for one year
title_short Lung function in adult patients with cystic fibrosis after using the eFlow(® )rapid for one year
title_sort lung function in adult patients with cystic fibrosis after using the eflow(® )rapid for one year
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353423/
https://www.ncbi.nlm.nih.gov/pubmed/21463983
http://dx.doi.org/10.1186/2047-783X-16-2-63
work_keys_str_mv AT naehrigs lungfunctioninadultpatientswithcysticfibrosisafterusingtheeflowrapidforoneyear
AT langs lungfunctioninadultpatientswithcysticfibrosisafterusingtheeflowrapidforoneyear
AT schifflh lungfunctioninadultpatientswithcysticfibrosisafterusingtheeflowrapidforoneyear
AT huberrm lungfunctioninadultpatientswithcysticfibrosisafterusingtheeflowrapidforoneyear
AT fischerr lungfunctioninadultpatientswithcysticfibrosisafterusingtheeflowrapidforoneyear